Verdence Capital Advisors LLC Purchases 386 Shares of Sanofi (NASDAQ:SNY)

Verdence Capital Advisors LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,909 shares of the company’s stock after acquiring an additional 386 shares during the period. Verdence Capital Advisors LLC’s holdings in Sanofi were worth $1,491,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Franklin Resources Inc. boosted its holdings in Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Natixis Advisors LLC boosted its holdings in Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the period. DAVENPORT & Co LLC lifted its stake in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after buying an additional 664,455 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $59.15 on Thursday. Sanofi has a 12-month low of $45.22 and a 12-month high of $59.19. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $150.11 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The firm has a 50-day moving average price of $52.22 and a 200 day moving average price of $52.68.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.